Korean Heart Rhythm Society 2019 Practical Guidelines on Antithrombotic Therapy for AF Patients Undergoing Percutaneous Coronary Intervention or Structural Heart Disease Intervention
10.3904/kjm.2019.94.4.330
- Author:
You Mi HWANG
1
;
Ji Hyun LEE
;
Ki Hong LEE
;
Woo Hyun LIM
;
Jaemin SHIM
;
Young Soo LEE
;
Jin Kyu PARK
;
Tae Hoon KIM
;
Jun KIM
;
Boyoung JOUNG
Author Information
1. Division of Cardiology, Department of Internal Medicine, St. Vincent's Hospital, Catholic University of Korea, Suwon, Korea.
- Publication Type:Randomized Controlled Trial
- Keywords:
Atrial fibrillation;
Anticoagulants;
Guideline;
Percutaneous coronary intervention
- MeSH:
Anticoagulants;
Aspirin;
Atrial Fibrillation;
Heart Diseases;
Heart;
Hemorrhage;
Humans;
Percutaneous Coronary Intervention;
Risk Assessment;
Warfarin
- From:Korean Journal of Medicine
2019;94(4):330-342
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The choice of an adequate antithrombotic regimen for atrial fibrillation patients undergoing emergent or elective percutaneous coronary intervention (PCI) should be based on the ischemic event and on the risk of bleeding. Recent randomized controlled trials have consistently demonstrated that dual antithrombotic therapeutic regimens, using non-vitamin K anticoagulants and clopidogrel, are superior to triple or dual therapy with warfarin and aspirin. This report incorporates findings of recent notable studies to provide concrete, clinically useful details and recommendations for bleeding risk assessment and optimal antithrombotic therapeutic strategies after PCI. In addition, we introduce guidelines for antithrombotic management after structural heart disease intervention.